Cdc42: Role in Cancer Management

• Published in: Chemical biology & drug design 2015-10, Vol.86 (4), p.432-439
• Main Authors: Qadir, Muhammad Imran, Parveen, Amna, Ali, Muhammad
• Format: Article
• Language: English
• Subjects: Animals; Antineoplastic Agents - chemical synthesis; Antineoplastic Agents - chemistry; Antineoplastic Agents - therapeutic use; Cdc42; cdc42 GTP-Binding Protein - antagonists & inhibitors; cdc42 GTP-Binding Protein - metabolism; Cell Division - drug effects; cell division control protein; Cell Movement - drug effects; Enzyme Inhibitors - chemical synthesis; Enzyme Inhibitors - chemistry; Enzyme Inhibitors - therapeutic use; GTPase-activating proteins; guanine exchange factor; Humans; Neoplasm Invasiveness; Neoplasm Proteins - antagonists & inhibitors; Neoplasm Proteins - metabolism; Neoplasms - drug therapy; Neoplasms - enzymology; Neoplasms - pathology
• ISSN: 1747-0277; 1747-0285
• DOI: 10.1111/cbdd.12556

Contribution of Cdc42, a member of Rho family, has been characterized for the beginning of variety of cellular responses including cellular transformation, cell division, cell invasion, migration, invadopodia formation, enzyme activity, filopodia formation, and cell polarity in cells. Deregulation of Cdc42 can alter the normal functioning of the cells, responsible for the initiation of signaling pathways and is correlated with several pathogenic processes such as cancer. Therefore, maintaining the level of Cdc42 and its effectors in cells, tumor progression can be controlled. Therefore, it can be suggested that deeper understanding about the Cdc42 contribution in cancer cell progression at molecular level can approach to the development of Cdc42 inhibitors in cancer management. Over expression of Cdc42 cause the bind of IQGAP with ß1 integrin whic in turns disrupt the cell adhesion and develop tumor progression.